NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 230 filers reported holding NEKTAR THERAPEUTICS in Q3 2022. The put-call ratio across all filers is 0.14 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $20 | -85.1% | 34,167 | -85.4% | 0.00% | -100.0% |
| Q2 2023 | $134 | -49.6% | 234,257 | -38.2% | 0.00% | -66.7% |
| Q1 2023 | $266 | -72.0% | 379,117 | -9.8% | 0.00% | -76.9% |
| Q4 2022 | $950 | -99.9% | 420,455 | +80.6% | 0.01% | +62.5% |
| Q3 2022 | $744,000 | +72.6% | 232,805 | +105.2% | 0.01% | +60.0% |
| Q2 2022 | $431,000 | -76.5% | 113,460 | -66.6% | 0.01% | -61.5% |
| Q1 2022 | $1,832,000 | +224.2% | 339,914 | +980.1% | 0.01% | +333.3% |
| Q3 2021 | $565,000 | +7.4% | 31,472 | +2.5% | 0.00% | -40.0% |
| Q2 2021 | $526,000 | +11.0% | 30,692 | +29.3% | 0.01% | 0.0% |
| Q1 2021 | $474,000 | +74.3% | 23,741 | +44.6% | 0.01% | -37.5% |
| Q3 2020 | $272,000 | -33.8% | 16,421 | -7.6% | 0.01% | -33.3% |
| Q2 2020 | $411,000 | +67.1% | 17,770 | +55.8% | 0.01% | +9.1% |
| Q4 2019 | $246,000 | -4.3% | 11,404 | -19.3% | 0.01% | -8.3% |
| Q3 2019 | $257,000 | -39.0% | 14,124 | +63.8% | 0.01% | -92.2% |
| Q2 2018 | $421,000 | – | 8,625 | – | 0.15% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TIRSCHWELL & LOEWY INC | 588,908 | $7,138,000 | 1.23% |
| Granahan Investment Management | 3,693,956 | $44,771,000 | 1.21% |
| NEA Management Company, LLC | 1,825,600 | $22,126,000 | 1.09% |
| FIC CAPITAL INC | 150,868 | $1,829,000 | 0.75% |
| Rhenman & Partners Asset Management AB | 181,797 | $2,203,000 | 0.66% |
| SOPHROSYNE CAPITAL LLC | 60,200 | $728,000 | 0.64% |
| HARVEY CAPITAL MANAGEMENT INC | 130,400 | $1,580,000 | 0.63% |
| Artal Group S.A. | 1,300,000 | $15,756,000 | 0.57% |
| BOGLE INVESTMENT MANAGEMENT L P /DE/ | 564,418 | $6,840,000 | 0.47% |
| OppenheimerFunds, Inc. | 24,400,000 | $295,728,000 | 0.35% |